Rome

• A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended recruitment
  2023-507443-10-00 5 2019-11-04 Patients with somatostatin receptor positive, well-differentiated G2 a
• This study will facilitate data collection of the long-term outcomes of pediatric subjects who have been treated in clinical trials with dab … Ended recruitment
  2023-509276-42-00 6 2019-10-30 Children and Adolescents with Cancers Harboring V600 mutation.
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Rela … Ended recruitment
  2023-507313-94-00 4 2019-10-18 Relapsing-Remitting Multiple Sclerosis (RRMS)
• A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended recruitment
  2024-510887-22-00 5 2019-09-30 Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
• Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas Ended recruitment
  2023-507886-25-00 4 2019-09-27 Previously untreated and symptomatic patients with histologically prov
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended recruitment
  2023-504821-38-00 4 2019-09-19 Classical Hodgkin lymphoma in children and young adults
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended recruitment
  2023-505980-36-00 5 2019-09-19 Primary progressive multiple sclerosis (PPMS)
• An efficacy and safety study of 2-OHOA in patients with glioblastoma Ended recruitment
  2024-511542-39-00 10 2019-09-16 Newly diagnosed primary glioblastoma multiforme (ndGBM)
• Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Stu … Ended recruitment
  2023-505321-14-00 10 2019-09-06 Warm Autoimmune Hemolytic Anemia
• Study for patients with Primary Hyperoxaluria to evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection Ended recruitment
  2024-512260-54-00 5 2019-08-20 Primary Hyperoxaluria
• Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini … Ended recruitment
  2024-511641-18-00 4 2019-08-01 Diffuse Large B-cell Lymphoma ABC
• Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine Ended recruitment
  2023-504930-23-00 5 2019-07-19 Episodic Migraine
• A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended recruitment
  2023-506153-38-00 5 2019-07-11 High-risk localized or locally advanced prostate cancer
• Avelumab Program Rollover Study Ended recruitment
  2024-514274-46-00 5 2019-06-21 Solid Tumors
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer
• A research study in children born small and who stayed small. Treatment is somapacitan once a week compared to Norditropin® once a day Ended recruitment
  2023-506830-66-00 4 2019-05-29 SGA - small for gestational age children
• A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilep … Ended recruitment
  2023-508681-15-00 4 2019-05-28 Adult focal (partial onset) epilepsy
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• A Trial for relapsed and relapsed/refractory multiple myeloma patients Ended recruitment
  2023-506733-30-00 4 2019-05-16 Multiple Myeloma relapsed and/or refractory
• An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens … Ended recruitment
  2023-509305-68-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed … Ended recruitment
  2024-513396-41-00 5 2019-05-15 PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR N
• GEN1046 Safety Trial in Patients With Malignant Solid Tumors Ended recruitment
  2023-509059-15-00 7 2019-04-30 Malignant solid tumors: endometrial carcinoma (EC), urothelial carcino
• Study of durvalumab or placebo administered with radiation therapy for patients with early stage non-small cell lung cancer Study of osime … Ended recruitment
  2024-512667-31-00 5 2019-04-23 Main cohort: Patients with unresected Stage I/II, lymph-node negative

Showing 1,585–1,608 of 2,096 trials